Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciluprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.75 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.34 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciluprevir SCHEMBL1735179 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL1736294 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL12300089 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL16199312 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL5152276 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL18671856 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL5152261 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL16438974 | 1.00 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL13915576 | 0.96 | ADRB3 (0.70) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL12154816 | 0.96 | ADRB3 (0.69) | ADRB3ADRA2BADRA2CCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-03-03 | — | — | US | claimed |
| EP-4619531-A1 | SELF-REPLICATING RNA AND USES THEREOF | Trustees of Boston University (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250059243-A1 | REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-02-20 | — | — | US | claimed |
| US-12202863-B2 | Chimeric antigen receptor (CAR) modulation | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-01-21 | — | — | US | claimed |
| WO-2025006719-A2 | REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-01-02 | — | — | WO | claimed |
| US-12180485-B2 | Repressible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-12-31 | — | — | US | claimed |
| WO-2024137990-A2 | COMPOSITIONS AND METHODS FOR CONTROLLED MRNA TRANSLATION AND STABILITY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-06-27 | — | — | WO | claimed |
| EP-4072596-A1 | METHOD AND COMPOSITIONS FOR REGULATED ARMORING OF CELLS | Senti Biosciences, Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| US-11453893-B2 | RNA-based delivery systems with levels of control | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-09-27 | — | — | US | claimed |
| WO-2022155500-A1 | SECRETABLE PAYLOAD REGULATION | SENTI BIOSCIENCES, INC. (US) | 2022-07-21 | — | — | WO | claimed |
| WO-2022133182-A1 | METHOD OF TREATING CORONAVIRUS INFECTION | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-31 | — | — | US | claimed |
| US-20220099672-A1 | Method for Treating and/or Preventing Bacteriophage Lysis During Fermentation | LOCUS SOLUTIONS, LLC | 2022-03-31 | — | — | US | claimed |
| US-20220090040-A1 | Fusion Constructs for Controlling Protein Function | SENTI BIOSCIENCES, INC. (US) | 2022-03-24 | — | — | US | claimed |
| EP-3969037-A2 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | Trustees of Boston University (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3947432-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | Trustees of Boston University (US) | 2022-02-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | ADAR, ADA, NSUN2 | ADRB3 3872/4885ADRA2B 3039/4885ADRA2C 2013/4885 |
| US-20250059243-A1 | REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS | BPTF, SRRT, TEAD3 | ADRB3 4752/4885ADRA2B 4726/4885ADRA2C 4734/4885 |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | ADRB3 3737/4885ADRA2B 3371/4885ADRA2C 3962/4885 |
| US-12202863-B2 | Chimeric antigen receptor (CAR) modulation | HAVCR2, CPB1, CTRL | ADRB3 3737/4885ADRA2B 3371/4885ADRA2C 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.